Further, patients suffering from AD or mild cognitive impairments display higher levels of osteopontin [77], which correlates with cognitive decline [78] and reduced BMD [79], while AD progression is linked to serum levels of the bone turnover markers osteopontin, osteocalcin and sclerostin [8]. The gene discussed is SOST; the disease is Alzheimer disease.